Frontal lobe dysfunction in progressive supranuclear palsy: Evidence for oxidative stress and mitochondrial impairment

Journal of Neurochemistry

Volumn 74, Issue 2, 2000, Pages 878-881

  Albers, David S ^a,b   Augood, Sarah J ^b   Park, Larry C H ^a   Browne, Susan E ^a,b   Martin, Deborah M ^b   Adamson, Jennifer ^c   Hutton, Michael ^c   Standaert, David G ^b   Vonsattel, Jean Paul G ^b   Gibson, Gary E ^b   Beal, M Flint ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Lipid peroxidation; Malondialdehyde; Mitochondrial dysfunction; Tauopathy

Indexed keywords

2 OXOGLUTARIC ACID;

ARTICLE; BRAIN METABOLISM; COMPLEX FORMATION; ENERGY METABOLISM; FRONTAL LOBE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MITOCHONDRIAL RESPIRATION; NERVE DEGENERATION; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY;

AGED; AGED, 80 AND OVER; CADAVER; FEMALE; FRONTAL LOBE; GLUTAMATE DEHYDROGENASE; HUMANS; KETOGLUTARATE DEHYDROGENASE COMPLEX; MALE; MALONDIALDEHYDE; MIDDLE AGED; MITOCHONDRIA; OXIDATIVE STRESS; REFERENCE VALUES; SUPRANUCLEAR PALSY, PROGRESSIVE;

EID: 18744435242     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2000.740878.x     Document Type: Article

References (37)

1. Albers D. S., Augood S. J., Martin D. M., Standaert D. G., Vonsattel J. P., and Beal M. F. (1999) Evidence for oxidative stress in the subthalamic nucleus in progressive supranuclear palsy. J. Neurochem. 73, 881-884.
2. Baker M., Litvan I., Houlden H., Adamson J., Dickson D., Perez-Tur J., Hardy J., Lynch T., Bigio E., and Hutton M. (1999) Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum. Mol. Genet. 8, 711-715.
3. Beal M. F. (1997) Oxidative damage in neurodegenerative diseases. Neuroscientist 3, 21-27.
4. Blin J., Baron J. C., Dubois B., and Pillon B. (1990) Positron emission tomography study in progressive supranuclear palsy. Arch. Neurol. 47, 747-752.
5. Browne S. E., Bowling A. C., Baik M. J., Gurney M., Browne R. H. Jr., and Beal M. F. (1998) Metabolic dysfunction in familial, but not sporadic, amyotrophic lateral sclerosis. J. Neurochem. 71, 281-287.
6. Chambers C. B., Lee J. M., Troncoso J. C.. Reich S., and Muma N. A. (1999) Overexpression of four-repeat tau mRNA isoforms in progressive supranuclear palsy but not in Alzheimer's disease. Ann Neurol. 46, 325-332.
7. Conrad C., Andreadis A., Trojanowski J. Q., Dickson D. W., Kang D., Chen X., Wiederholt W., Hansen L., Masliah E., Thal L. J., Katzman R., Xia Y., and Saitoh T. (1997) Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann. Neurol. 41, 277-281.
8. D'Antona R., Baron J. C., Samson Y., Serdaru M., Viader F., Agid Y., and Cambier J. (1985) Subcortical dementia: frontal cortex hypometabolism detected by positron emission tomography in patients with progressive supranuclear palsy. Brain 108, 785-799.
9. Dickson D. W., Kress Y., Crowe A., and Yen S. H. (1985) Monoclonal antibodies to Alzheimer neurofibrillary tangles. 2. Demonstration of a common antigenic determinant between ANT and neurofibrillary degeneration in progressive supranuclear palsy. Am. J. Pathol. 120, 292-303.
10. DiMonte D., Harati Y., Jankovic J., Sandy M. S., Jewell S. A., and Langston J. W. (1994) Muscle mitochondrial ATP production in progressive supranuclear palsy. J. Neurochem. 62, 1631-1634.
11. Feany M. and Dickson D. (1996) Neurodegenerative disorders with extensive tau pathology: a comparative study and review. Ann. Neurol. 40, 139-148.
12. Foster N. L., Gilman S., Berent S., Morin E., Brown M. B., and Koeppe R. A. (1988) Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography. Ann. Neurol. 24, 399-406.
13. Gibson G. E., Zhang H., Sheu K. F.-R., Bogdanovich N., Lindsay J. G., Lannfelt L., Vestling M., and Cowburn R. F. (1998) α-Ketoglutarate dehydrogenase in Alzheimer brains bearing the APP670/ 671 mutation. Ann. Neurol. 44, 676-681.
14. Goedert M., Spillantini M. G., Jakes R., Rutherford D., and Crowther R. A. (1989a) Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 3, 519-526.
15. Goedert M., Spillantini M. G., Potier M. C., Ulrich J., and Crowther R. A. (1989b) Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 8, 393-399.
16. Goffinet A. M., DeVolder A. G., Gillian C., Rectem D., Bol A., Michel C., Cogneau M., Labar D., and Laterre C. (1989) Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy. Ann. Neurol. 25, 131-139.
17. Golbe L., Davis P., Schoenberg B., and Duvoisin R. (1988) Prevalence and natural history of progressive supranuclear palsy. Neurology 38, 1031-1034.
18. Halliwell B. and Chirico S. (1993) Lipid peroxidation: its mechanism, measurement, and significance. Am. J. Clin. Nutr. 57 (Suppl.), 715S-724S; discussion 724S-725S.
19. Hauw J. J., Daniel S. E., Dickson D., Horoupian D. S., Jellinger K., Lantos P. L., McKee A., Tabaton M., and Litvan I. (1994) Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 44, 2015-2019.
20. Hensley K., Hall N., Subramaniam R., Cole P., Harris M., Aksenov M., Aksenova M., Gabbita S. P., Wu J. R. Carney J. M., Lovell M., Markesbery W. R., and Butterfield D. A. (1995) Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
21. Higgins J. J., Litvan I., Nee L. E., and Loveless J. M. (1999) A lack of the R406W tau mutation in progressive supranuclear palsy and corticobasal degeneration. Neurology 52, 404-406.
22. Hong M., Zhukareva V., Vogelsberg-Ragaglia V., Wszolek Z., Reed L., Miller B. I., Geschwind D. H., Bird T. D., McKeel D., Goate A., Morris J. C., Wilhelmsen K. C., Schellenberg G. D., Trojanowski J. Q., and Lee V. M. (1998) Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282, 1914-1917.
23. Hutton M., Lendon C. L., Rizzu P., Baker M., Froelich S., Houlden H., Pickering-Brown S., Chakraverty S., Isaacs A., Graver A., Hackett J., Adamson J., Lincoln S., Dickson D., Davies P., Petersen R. C., Stevens M., de Graaff E., Wauters E., van Baren J., Hillebrand M., Joosse M., Kwon J. M., Nowotny P., Heutink P., et al. (1998) Association of missense and 5́-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705.
24. Johnson K. A., Sperling R. A., Holman B. L., Nagel J. S., and Growdon J. H. (1992) Cerebral perfusion in progressive supranuclear palsy. J. Nuclear Med. 33, 704-709.
25. Kobayashi T., Matsumine H., Matuda S., and Mizuno Y. (1998) Association between the gene encoding the E2 subunit of the α-ketoglutarate dehydrogenase complex and Parkinson's disease. Ann. Neurol. 43, 120-123.
26. 10. Ann. Neurol. 41, 160-165.
27. Litvan I., Hauw J., Bartko J., Lantos P. L., Daniel S. E., Horoupian D. S., McKee A., Dickson D., Bancher C., Tabaton M., Jellinger K., and Anderson D. W. (1996a) Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J. Neuropathol. Exp. Neurol. 55, 97-105.
28. Litvan I., Mangone C. A., McKee A., Verny M., Parsa A., Jellinger K., D'Olhaberriague L., Chaudhuri K. R., and Pearce R. K. B. (1996b) Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J. Neurol. Neurosurg. Psychiatry 61, 615-620.
29. Mattson M., Fu W., Waeg G., and Uchida K. (1997) 4-Hydroxynoneal, a product of lipid peroxidation, inhibits dephosphorylation of the microtubule-associated protein tau. Neuroreport 8, 2275-2281.
30. Mecocci P., MacGarvey U., Kaufman A. E., Koontz D., Shoffner J. M., Wallace D. C., and Beal M. F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain. Ann. Neurol. 34, 609-616.
31. Nunomura A., Perry G., Pappolla M. A., Wade R., Hirai K., Chiba S., and Smith M. A. (1999) RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J. Neurosci. 19, 1959-1964.
32. Poorkaj P., Bird T. D., Wijsman E., Nemens E., Garruto R. M., Anderson L., Andreadis A., Wiederholt W. C., Raskind M., and Schellenberg G. D. (1998) Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43, 815-825.
33. Robbins T. W., James M., Owen A. M., Lange K. W., Lees A. J., Leigh P. N., Marsden C. M., Quinn N. P., and Summers B. A. (1994) Cognitive deficits in progressive supranuclear palsy, Parkinson's disease, and multiple system atrophy in tests sensitive to frontal lobe dysfunction. J. Neurol. Neurosurg. Psychiatry 57, 79-88.
34. Sergeant N., Wattez A., and Delacourte A. (1999) Neurofibrillary degeneration in progressive supranuclear palsy and corticobasal degeneration: tau pathologies with exclusively "exon 10" isoforms. J. Neurochem. 72, 1243-1249.
35. 10 in parkisonian patients. Neurology 50, 793-795.
36. Spillantini M. G., Murrell J. R., Goedert M., Farlow M. R., Klug A., and Ghetti B. (1998) Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Null. Acad. Sci. USA 95, 7737-7741.
37. Steele J., Richardson J., and Olszewski J. (1964) Progressive supranuclear palsy. A heterogeneous degeneration involving the brainstem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch. Neurol. 10, 333-359.